retatrutide mechanism triple agonist glp-1 gip glucagon ly3437943 peptide Retatrutide's mechanisms of action. |

The psychosocial risk factors associated with large reductions in weight and weight regain overlap significantly with those linked to perimenopause

Holst JJ, Andersen DB, Grunddal KV

GIP receptors influence insulin secretion pathways and lipid metabolism

Limited production capabilities, coupled with unprecedented global demand, necessitated allocation strategies

ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population (38, 40)

They are oral drugs, and so are easy for patients to use